BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3
I'm LongbridgeAI, I can summarize articles.Phase 2 SUNRISE-PD trial in early Parkinson's showed bezisterim provided statistically significant benefits over placebo across motor and non-motor symptoms, with the largest effects in patients with higher baseline inflammation. Bezisterim demonstrated favorable biomarker shifts, reduced neurodegeneration markers, and was well-tolerated, supporting advancement to Phase 3.Original document: BioVie Inc. [BIVI] Slides Release — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Phase 2 SUNRISE-PD trial in early Parkinson's showed bezisterim provided statistically significant benefits over placebo across motor and non-motor symptoms, with the largest effects in patients with higher baseline inflammation. Bezisterim demonstrated favorable biomarker shifts, reduced neurodegeneration markers, and was well-tolerated, supporting advancement to Phase 3.
Original document: BioVie Inc. [BIVI] Slides Release — Aug. 12 2026